Affichem

Affichem was founded in 2002, with the mission to design, develop and market innovative therapeutic molecules and theranostic markers for the treatment of cancer and neurodegenerative diseases.

Affichem is currently running preclinical testing of a regenerative drug which stimulates differentiation of neural progenitors and promotes the functional state of neurons or neuron-derived cells, including spiral ganglion neurons that transmit sound information from the cochlea to the brain.

Clinical trials to be announced.

RECENT NEWS ON AFFICHEM

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Affichem

Locations: France, United States
Year Founded: 2002
CEO: United States: Jennifer Seibert (MBA, MSc.) France: Stéphane Silvente (MS, MBA)